Novartis AG (NOVN) plans to close two sites in Europe, move staff from California to the Boston area and cut about 500 jobs in an effort consolidate its research operations, especially in respiratory diseases.
Novartis plans to close sites in Horsham, England, and Vienna and move cancer research from Emeryville, California, to Cambridge, Massachusetts, Eric Althoff, a spokesman for the company, said in an e-mailed statement today. The biotherapeutics development unit in La Jolla, California, will be closed, he said.
The changes come as the company’s new chairman, Joerg Reinhardt, is scrutinizing Novartis’s operations. Reinhardt began a review of the portfolio after taking over in August, and has said Basel, Switzerland-based Novartis wants its businesses to be among the industry leaders or will otherwise consider divesting them. Novartis employs more than 125,000 people.
Chosen excerpts by Job Market Monitor. Read the whole story at
via Novartis to Cut 500 Jobs in U.S., Europe in Research Revamp – Businessweek.
Related Posts
Layoffs in Pharmaceutical Industry / Due to Productivity Crisis in R&D ?
The number of new drugs approved per billion US dollars spent on R&D by the pharmaceutical industry fell by half roughly every 9 years since 1950 Continue reading »
Valeant Pharma ( Bausch & Lomb ) / To cut 10-15 percent jobs
Canada’s Valeant Pharmaceuticals International Inc (VRX.TO: Quote) (VRX.N: Quote), which has offered to buy Bausch & Lomb Holdings for $8.7 billion, said it may slash 10 to 15 percent of the combined company’s workforce. Valeant, which expects to get regulatory nod by early August, said severance plans for the United States and Canada have been … Continue reading »
The Top 10 Pharma Layoffs of 2012
By the beginning of 2012, the pharma industry had endured one of the biggest shakeouts in the industry’s history. Tens of thousands of jobs had been eliminated, and most employees had good reason to fear they would be next. Just after the New Year, PharmaIQ reported that a survey revealed that 44% of the people … Continue reading »
Biopharma – Job Outlook Bleak
After years of flying high, biopharma job growth is running into turbulence, a number of factors have increasingly pushed big pharma into layoffs. Although the picture is bleak now, the industry’s longer-term employment prospects appear brighter. Roche will eliminate 1,000 jobs by the end of 2013 when it shuts down its Nutley, NJ, R&D site. … Continue reading »
Merck pharma closes Swiss HQ- 580 jobs
The job losses at biotech firm Merck Serono were part of a wider restructuring plan “to create a leaner, more agile organisation,” the company said in a statement. “The planned measures for Merck Serono’s operations in Switzerland are needed to ensure our global competitive position in a rapidly changing market and to secure the long-term … Continue reading »
Pharmaceutical group Mylan is to create 500 jobs in Dublin and Galway
Those jobs will be created over the next five years following a €380 million investment in its Irish operations. The investment, which is being supported by IDA Ireland, will include an expansion of Mylan’s research and development (R&D) capabilities here. Mylan is the largest so-called “generics” pharmaceutical manufacturer in Ireland, producing medicines that are no … Continue reading »
Merck / Job cuts rise by 8,500 to 16,000
Merck job cuts mean the drugmaker is slashing about 20 percent of its workforce. 8,500 jobs will be added to the 7,500 Merck job cuts already announced, bringing the total to 16,000. Continue reading»
Job Market Monitor 
Discussion
Trackbacks/Pingbacks
Pingback: Pharmaceutical / The Skills Gap | Job Market Monitor - November 20, 2013